Figure 1.
Sample and mutation distribution of patients with PD as assessed by INV. PD samples for each study cohort (A), with BTK and/or PLCG2 mutation distribution (B). Ibr, ibrutinib; Zanu, zanubrutinib.
Sample and mutation distribution of patients with PD as assessed by INV. PD samples for each study cohort (A), with BTK and/or PLCG2 mutation distribution (B). Ibr, ibrutinib; Zanu, zanubrutinib.
